Berry Genomics Co Ltd (000710) - Total Liabilities
Based on the latest financial reports, Berry Genomics Co Ltd (000710) has total liabilities worth CN¥694.43 Million CNY (≈ $101.62 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Berry Genomics Co Ltd to see how much of total assets are deployed in long-term investments.
Berry Genomics Co Ltd - Total Liabilities Trend (1994–2024)
This chart illustrates how Berry Genomics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 000710 asset base.
Berry Genomics Co Ltd Competitors by Total Liabilities
The table below lists competitors of Berry Genomics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Sonavox Electronics Co. Ltd. A
SHG:688533
|
China | CN¥1.96 Billion |
|
SPAR Group Ltd
JSE:SPP
|
South Africa | ZAC40.91 Billion |
|
Changzhou Langbo Seal Polytron Technologies Co Ltd Class A
SHG:603655
|
China | CN¥43.24 Million |
|
Dolphin Drilling AS
OL:DDRIL
|
Norway | Nkr189.80 Million |
|
Cedar Development Co Ltd
SHE:002485
|
China | CN¥522.50 Million |
|
Abaxx Technologies Inc
NEO:ABXX
|
Canada | CA$45.79 Million |
|
VersaBank
NASDAQ:VBNK
|
USA | $5.61 Billion |
|
BlackRock Limited Duration Income Trust
NYSE:BLW
|
USA | $308.21 Million |
Liability Composition Analysis (1994–2024)
This chart breaks down Berry Genomics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 000710 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Berry Genomics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Berry Genomics Co Ltd (1994–2024)
The table below shows the annual total liabilities of Berry Genomics Co Ltd from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥669.56 Million ≈ $97.98 Million |
-20.91% |
| 2023-12-31 | CN¥846.56 Million ≈ $123.88 Million |
-2.87% |
| 2022-12-31 | CN¥871.54 Million ≈ $127.53 Million |
-12.50% |
| 2021-12-31 | CN¥996.02 Million ≈ $145.75 Million |
+21.24% |
| 2020-12-31 | CN¥821.52 Million ≈ $120.21 Million |
+13.81% |
| 2019-12-31 | CN¥721.83 Million ≈ $105.63 Million |
+206.28% |
| 2018-12-31 | CN¥235.68 Million ≈ $34.49 Million |
-4.17% |
| 2017-12-31 | CN¥245.94 Million ≈ $35.99 Million |
-43.33% |
| 2016-12-31 | CN¥433.97 Million ≈ $63.50 Million |
+13.84% |
| 2015-12-31 | CN¥381.19 Million ≈ $55.78 Million |
+20.70% |
| 2014-12-31 | CN¥315.83 Million ≈ $46.22 Million |
+9.25% |
| 2013-12-31 | CN¥289.09 Million ≈ $42.30 Million |
+33.01% |
| 2012-12-31 | CN¥217.34 Million ≈ $31.80 Million |
-6.61% |
| 2011-12-31 | CN¥232.73 Million ≈ $34.06 Million |
-10.85% |
| 2010-12-31 | CN¥261.04 Million ≈ $38.20 Million |
+3.78% |
| 2009-12-31 | CN¥251.54 Million ≈ $36.81 Million |
+21.55% |
| 2008-12-31 | CN¥206.93 Million ≈ $30.28 Million |
+57.32% |
| 2007-12-31 | CN¥131.54 Million ≈ $19.25 Million |
-9.20% |
| 2006-12-31 | CN¥144.87 Million ≈ $21.20 Million |
+7.10% |
| 2005-12-31 | CN¥135.26 Million ≈ $19.79 Million |
-18.41% |
| 2004-12-31 | CN¥165.77 Million ≈ $24.26 Million |
+13.31% |
| 2003-12-31 | CN¥146.30 Million ≈ $21.41 Million |
+9.82% |
| 2002-12-31 | CN¥133.22 Million ≈ $19.49 Million |
-31.96% |
| 2001-12-31 | CN¥195.81 Million ≈ $28.65 Million |
+56.24% |
| 2000-12-31 | CN¥125.33 Million ≈ $18.34 Million |
+61.14% |
| 1999-12-31 | CN¥77.77 Million ≈ $11.38 Million |
-19.27% |
| 1998-12-31 | CN¥96.34 Million ≈ $14.10 Million |
-7.65% |
| 1997-12-31 | CN¥104.33 Million ≈ $15.27 Million |
-16.64% |
| 1996-12-31 | CN¥125.15 Million ≈ $18.31 Million |
+31.18% |
| 1995-12-31 | CN¥95.40 Million ≈ $13.96 Million |
+55.54% |
| 1994-12-31 | CN¥61.33 Million ≈ $8.98 Million |
-- |
About Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcri… Read more